Top 10 Criteria Investors Want To See in a Business Plan

Loading...
November 15, 2003

1 Proof of concept. Demonstrate a tangible and viable product. Experimental betas should be field-tested or put through simulation.

2 Product diversification. A software designer that commits resources to developing a broad portfolio of applications signals that biodefense is a core business, not just a pet project on the side, and increases funding potential. A combination of hardware and software with mission-specific technology covering diagnostics, mitigation, communication, and recovery flags the firm's versatility and potential profitability by servicing different buyer needs.

3 Product track record. A developer might boast about its overall success in DNA mapping, highlighting examples of prior genomic work using its software. Successful civilian sales can be a good indicator of how revamped applied technology in the defense arena can perform.

4 Scientific talent. A biodefense firm's brain trust should include talent with intense research, academic, engineering, medical, and product development experience. Investors will also look for those who have had careers in or connections with the military, inspiring confidence that managers know how the science can be practically applied to the mission at hand.

5 Knowledgeable managers. While arguably a CEO's main job is business development and navigating politics, he or she should also be highly conversant technically. It wouldn't hurt to have a former medical doctor or lab scientist take the head honcho's seat. The client expects software developers be tuned in to biotechnology issues as much as they are with computer issues.

6 Good connections. Skittish investment bankers will preferentially back firms that have secured previous biodefense funding from one of the federal agencies, venture funds, or grant programs. The rationale is that if the government — the leading client of these products — will back you, then a private investor should as well.

7 Cash is still king. Show that you made efficient use of that cash flow without squandering large sums on overhead.

8 Team player. Also valued are joint venture and consortium relationships with name-brand defense firms. If you successfully team up with a Northrop Grumman or a Computer Associates, that's a winning strategy.

9 The beat of your own drummer. Venture investors like one-of-a-kind proprietary products. The ability for a company to own its niche increases the chance of success.

10 Efficiency. Demonstrate that your operation can mass-produce and deliver large quantities on demand when and where the client wants it.

—Jason B. Lee



Back to Profiting from the BioShield 



White Papers & Special Reports

oracle_RDC
Remote Data Capture:Acquisition and Analysis
Sponsored by Oracle

See why Electronic Data Capture (EDC) is gaining traction in the pharmaceutical
clinical trials arena. Today approximately half of all clinical trials are conducted
electronically, and the figure is rapidly rising. Report includes contributions from
Oracle Health Sciences, Pfizer, PPD, and C3i.

 



oracle20723
The Role of Analytics in Transforming Healthcare
Sponsored by Oracle

Sharing many of the data challenges and opportunities faced by Healthcare, the Life Sciences industry remains focused on delivering new, innovative therapies and solutions to patients in a cost effective, timely and safe way. With spiraling R&D costs, new methods such as adaptive trials, and never ending need for deep pharmacovigilance, the Life Sciences companies that effectively use analytics to explore, monitor and optimize their business will rapidly become the new leaders.

Oracle’s strategy—built upon Enterprise Health Analytics and Health Data Warehouse Foundation—provides a powerful, practical, and extensible approach to delivering the IT analytics infrastructure required to confront the worldwide healthcare challenge.



pegasystems
BPM-Based Case Management Approach to Optimizing Clinical Trial Efficiency
Sponsored by Pegasystems

Business Process Management (BPM) software offers liberation in the planning and management of clinical trials today. SmartBPM provides the components for automating critical clinical trial processes ranging from protocol development and patient enrollment to site management and investigator payments. Advantages are:

  • Potentially stunning return on investment at multiple levels.
  • A 500%, or better, increase in application development time by directly executing business requirements
  • Improved customer retention
  • A 50% possible reduction in training time

Discovered is opportunity to enhance relationships with investigators, subjects, and regulators while bringing momentum to a technology-impaired study startup phase. Learn more about SmartBPM in this complimentary white paper.



Job Openings

mskc logo
Software Engineer – Computational Biology Center

Memorial Sloan-Kettering Cancer Center seeks an Engineer to design and develop complex data analysis systems in support of cancer genomics research projects at the Computational Biology Center. Qualified candidate will have a BA, 5+ years of software development experience and expert knowledge of Java, SQL, and HTML.

Apply: www.mskcciscareers.org.  Equal opportunity and affirmative action employer.

Web Symposia
Loading...

Bio-IT World proudly presents the Bio-IT World Web Symposia Series!

Covering a broad array of topics within the life sciences and drug development industries, these complimentary 90-minute web symposiums provide an interactive platform to learn more about cutting-edge bio-IT topics through expert analysis and discussions.

Leveraging BPM to Increase Efficiencies in Clinical Trial Case Management
Recorded on August 3, 2010
Sponsored by: Pegasystems
Program Details | Access Recording 

Next Gen Data Management for Next Gen Life Sciences
September 8, 2010 | 1:00pm - 2:30pm EST
Sponsored by Quantum
Program Details | Register Today 

 


Loading...

For reprints and/or copyright permission, please contact The YGS Group, 3650 West Market Street, York, PA;

(717) 505-9701 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.